OCTOBER TRIPS COUNCIL MEETING
October 24-25, 2011
Canada’s Intervention for Agenda Item G (Access to Medicines)
Mr. Chairman, Canada welcomes this opportunity to discuss the implementation of the Paragraph 6 system and to share some thoughts on the issue of access to medicines.
Continue Reading →
Register of Copyrights Maria A. Pallante has made public the “priorities and special projects” of the US Copyright Office from October 2011 to October 2013. The ambitious work plan sets 17 priorities in the areas of copyright policy and administrative practices, and 10 special projects “to improve the quality and efficiency of the U.S. Copyright Office’s services.”
The 16 page document is available here
Comments should be sent to registerofcopyrights@copyright.gov
Here’s a quick outline:
3 Studies
Continue Reading →
2010
April 29, 2010.
Brand name: Provenge
Generic name: Sipuleucel-T
Marketed by: Dendreon
Indication: therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.
FDA press release here.
US Price: $31,000 per infusion. A full course of treatment is three infusions over a one-month period, or $93k.
Continue Reading →
This note begins by looking at patents issued by the USPTO that specifically mention the term ritonavir in the patent claims, or mention the NIH contract that was used to fund the early development of the product. This includes 194 patents that cite ritonavir in the patent claims, and another 42 patents that cite the NIH contact that funded the early ritonavir work. We also provide quotes from an August 19, 2011 WIPO report on the patent landscape for ritonavir that found 805 patent families related to ritonavir.
Continue Reading →
The following excerpts are from an exchange of messages on ip-health about a recent recent petition regarding the patent pool that has been posted to several public health email lists. Among the leaders in the petition are apparently ITPC and the New York based I-MAK. ITPC has a long history of advocating for the interests of persons living with HIV, and I-MAK has for many years sought to overcome patent barriers for access to medicines. A copy of the petition is here http://www.petitionbuzz.com/petitions/mppunitaid.
Continue Reading →
On 4-5 October 2011, UNITAID held its third Consultative Forum giving stakeholders the opportunity to view UNITAID’s achievements to date as well as provide input on UNITAID’s activities moving forward. Attendees at the forum included civil society, NGOs, implementing partners, representatives from the pharmaceutical industry and private foundations, and governmental officials. Several of the presentations from the IP workshop as well as the recommendations from the IP workshop are attached below.
Continue Reading →
Ted is a Public Service Institute Research Fellow at Knowledge Ecology International. He is a recent graduate of the University of Notre Dame Law School. During his law school career, he interned at a variety of public service and public policy organizations, including the United States Navy JAG, the Department of Justice, and Opportunity Maine, a grassroot advocacy organization.
Continue Reading →
Two areas where ACTA is inconsistent with US law, injunctions and damages
KEI Policy Brief, 2011:2
30 September 2011, revised 3 October 2011
James Love and Krista Cox
As the U.S. is reportedly about to sign ACTA, we wanted to point out two important areas where ACTA is not consistent with U.S. law. These are the sections of ACTA dealing with injunctions and damages. Below we have included the text from ACTA and the WTO TRIPS agreement on these two topics.
Continue Reading →